Supercharge Your Innovation With Domain-Expert AI Agents!

Procalcitonin for prognosis of adverse events

An adverse event, procalcitonin technology, applied in the field of clinical diagnostics, can solve problems such as elevation

Active Publication Date: 2015-08-19
BRAHMS GMBH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is unknown whether relatively elevated PCT concentrations in healthy individuals can be linked to the development of potential future adverse events

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Procalcitonin for prognosis of adverse events
  • Procalcitonin for prognosis of adverse events
  • Procalcitonin for prognosis of adverse events

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0058] Study population and design

[0059] The study population was from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study. The PREVEND study was designed to prospectively investigate the intrinsic course of proteinuria and its relationship to renal function in a large cohort drawn from the general population (age range 28 to 75 years) in Groningen, The Netherlands relationship with cardiovascular disease. Details of study design, recruitment, and procedures have been published elsewhere (Hillege et al., Circulation 2002, 106:1777-1782; Hillege et al., J Intern Med 2001, 249:519-526; Mahmoodi et al., JAMA 2009, 301:1790-1790- 1797). The PREVEND study was approved by the local medical ethics committee, University Medical Center Groningen, and complied with the principles outlined in the Declaration of Helsinki. All participants gave written informed consent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event.

Description

technical field [0001] The field of the invention is clinical diagnostics. In particular, the present invention relates to the determination of procalcitonin (PCT) levels in a sample of body fluid from a subject. Background technique [0002] Procalcitonin (PCT) is considered a biomarker that reflects the presence and severity of local and systemic bacterial infection, ie, sepsis (Assicot et al., Lancet 1993; 341:515-8; Muller et al., Crit Care Med 2000 28:977-83; Harbarth et al., Am J Respir Crit Care Med 2001;164:396-402; Becker et al., Crit Care Med 2008;36:941-52; Becker et al., J Clin Endocrinol Metab 2004:89:1512 -25; Nobre et al., Am J Respir Crit Care Med 2008 177:498-505; Christ-Crain et al., Lancet 2004;363:600-7; Stolz et al., Chest 2007;131:9-19; J Respir Crit Care Med 2006;174:84-93; Briel et al., Arch Intern Med 2008;168:2000-7; discussion 7-8). [0003] During bacterial infection, plasma PCT concentrations are typically above 0.25 ng / mL. Recently, by using...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/68
CPCG01N2800/324G01N2800/042G01N2800/2871G01N2800/50G01N33/6893G01N2333/585
Inventor 约阿希姆·斯特鲁克S·J·L·巴克尔
Owner BRAHMS GMBH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com